Loading...

Advanced Proteome Therapeutics

DB:0E8
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0E8
DB
CA$4M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Advanced Proteome Therapeutics has significant price volatility in the past 3 months.
0E8 Share Price and Events
7 Day Returns
0%
DB:0E8
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
17.6%
DB:0E8
-7.4%
DE Biotechs
-5.6%
DE Market
0E8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Advanced Proteome Therapeutics (0E8) 0% 0% 100% 17.6% -25.9% -86.7%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 0E8 outperformed the Biotechs industry which returned -7.4% over the past year.
  • 0E8 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
0E8
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Advanced Proteome Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Advanced Proteome Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.02.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Advanced Proteome Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Advanced Proteome Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0E8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $0.00
TSXV:APC Share Price ** TSXV (2019-04-24) in CAD CA$0.03
TSXV:APC Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.741 $0.02
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Advanced Proteome Therapeutics.

DB:0E8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:APC Share Price ÷ EPS (both in USD)

= 0.02 ÷ 0.00

-103.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Advanced Proteome Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Advanced Proteome Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Advanced Proteome Therapeutics's expected growth come at a high price?
Raw Data
DB:0E8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -103.49x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Advanced Proteome Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Advanced Proteome Therapeutics's assets?
Raw Data
DB:0E8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $0.00
TSXV:APC Share Price * TSXV (2019-04-24) in CAD CA$0.03
TSXV:APC Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.741 $0.02
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:0E8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:APC Share Price ÷ Book Value per Share (both in USD)

= 0.02 ÷ 0.00

4.91x

* Primary Listing of Advanced Proteome Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Advanced Proteome Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Advanced Proteome Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Advanced Proteome Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Advanced Proteome Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Proteome Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Advanced Proteome Therapeutics expected to grow at an attractive rate?
  • Unable to compare Advanced Proteome Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Advanced Proteome Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Advanced Proteome Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0E8 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0E8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0E8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 -1 0
2018-10-31 -1 -1
2018-07-31 -1 -1
2018-04-30 -1 0
2018-01-31 -1 -1
2017-10-31 -1 -1
2017-07-31 -1 -1
2017-04-30 -1 -1
2017-01-31 -1 -1
2016-10-31 -1 -1
2016-07-31 -1 -1
2016-04-30 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Advanced Proteome Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Advanced Proteome Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0E8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Advanced Proteome Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0E8 Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 0.00
2018-10-31 -0.01
2018-07-31 0.00
2018-04-30 0.00
2018-01-31 -0.01
2017-10-31 -0.01
2017-07-31 -0.01
2017-04-30 -0.01
2017-01-31 -0.01
2016-10-31 -0.01
2016-07-31 -0.01
2016-04-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Advanced Proteome Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 0E8’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Advanced Proteome Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Advanced Proteome Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Advanced Proteome Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Advanced Proteome Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Advanced Proteome Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Advanced Proteome Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Advanced Proteome Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Advanced Proteome Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Advanced Proteome Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Advanced Proteome Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Advanced Proteome Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0E8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 -0.03 1.00
2018-10-31 -0.80 1.05
2018-07-31 -0.74 1.05
2018-04-30 -0.50 1.05
2018-01-31 -1.11 1.08
2017-10-31 -0.69 1.08
2017-07-31 -0.72 1.02
2017-04-30 -0.82 0.99
2017-01-31 -0.77 0.89
2016-10-31 -0.72 0.84
2016-07-31 -0.67 0.82
2016-04-30 -0.67 0.84
2016-01-31 -0.84 0.90
2015-10-31 -0.89 0.99
2015-07-31 -0.89 1.28
2015-04-30 -0.25 1.26
2015-01-31 0.25 1.27
2014-10-31 -1.20 1.19
2014-07-31 -1.15 0.94
2014-04-30 -1.74 0.88
2014-01-31 -2.35 0.87
2013-10-31 -0.95 0.92
2013-07-31 -1.02 0.94
2013-04-30 -1.08 1.03
2013-01-31 -0.87 1.00
2012-10-31 -0.75 0.92
2012-07-31 -0.76 0.84
2012-04-30 -0.60 0.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Advanced Proteome Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Advanced Proteome Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Advanced Proteome Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Advanced Proteome Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Advanced Proteome Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Advanced Proteome Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Advanced Proteome Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Advanced Proteome Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Advanced Proteome Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Advanced Proteome Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Advanced Proteome Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Advanced Proteome Therapeutics Company Filings, last reported 2 months ago.

DB:0E8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 -0.89 0.21 0.05
2018-10-31 -1.00 0.21 0.17
2018-07-31 -0.90 0.21 0.14
2018-04-30 -0.56 0.21 0.36
2018-01-31 -1.26 0.32 0.05
2017-10-31 -0.59 0.26 0.29
2017-07-31 -0.79 0.32 0.14
2017-04-30 -0.78 0.38 0.08
2017-01-31 -0.69 0.19 0.08
2016-10-31 -0.65 0.19 0.07
2016-07-31 -0.49 0.15 0.07
2016-04-30 -0.35 0.15 0.09
2016-01-31 -0.17 0.15 0.27
2015-10-31 0.03 0.15 0.47
2015-07-31 0.20 0.15 0.67
2015-04-30 0.02 0.15 0.50
2015-01-31 0.09 0.15 0.57
2014-10-31 0.29 0.15 0.83
2014-07-31 -0.41 0.15 0.70
2014-04-30 -1.21 0.15 0.69
2014-01-31 -2.00 0.16 0.56
2013-10-31 -0.68 0.16 0.19
2013-07-31 -0.72 0.16 0.13
2013-04-30 -0.45 0.16 0.33
2013-01-31 -0.56 0.33 0.03
2012-10-31 -0.33 0.32 0.13
2012-07-31 -0.37 0.31 0.03
2012-04-30 -0.29 0.34 0.04
  • Advanced Proteome Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Advanced Proteome Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Advanced Proteome Therapeutics has less than a year of cash runway based on current free cash flow.
  • Advanced Proteome Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.2% each year.
X
Financial health checks
We assess Advanced Proteome Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Advanced Proteome Therapeutics has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Advanced Proteome Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Advanced Proteome Therapeutics dividends.
If you bought €2,000 of Advanced Proteome Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Advanced Proteome Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Advanced Proteome Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0E8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Advanced Proteome Therapeutics has not reported any payouts.
  • Unable to verify if Advanced Proteome Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Advanced Proteome Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Advanced Proteome Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Advanced Proteome Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Advanced Proteome Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Advanced Proteome Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Advanced Proteome Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Woodward
COMPENSATION $0
AGE 57
TENURE AS CEO 0.3 years
CEO Bio

Mr. Paul Woodward serves as President Chief Executive Officer & Director at Aether Catalyst Solutions, Inc. Mr. Woodward serves as the President & Director of Conation Capital Corp. Mr. Woodward was investment banker with 30 years of experience in venture markets and has extensive experience in capital markets and corporate finance. He has been a Member of Advisory Board for Advanced Proteome Therapeutics Corporation since May 22, 2012 and Director since April 13, 2018. He has been President and CEO of Advanced Proteome Therapeutics Corporation since December, 2018. He is also the President, Chief Financial Officer and a director of Railtown Capital Corporation, since August 2016. He holds a Bachelor of Arts (Econ) from Simon Fraser University in Burnaby, British Columbia.

CEO Compensation
  • Insufficient data for Paul to compare compensation growth.
  • Paul's remuneration is lower than average for companies of similar size in Germany.
Management Team

Paul Woodward

TITLE
President
AGE
57
TENURE
0.3 yrs

Ken Phillippe

TITLE
Chief Financial Officer
COMPENSATION
$17K
AGE
66
TENURE
10.1 yrs
Board of Directors Tenure

Average tenure and age of the Advanced Proteome Therapeutics board of directors in years:

0.9
Average Tenure
57
Average Age
  • The average tenure for the Advanced Proteome Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ben Catalano

TITLE
Director
COMPENSATION
$7K
AGE
53
TENURE
0.3 yrs

Paul Woodward

TITLE
President
AGE
57
TENURE
1 yrs

Paul Wender

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

David Webb

TITLE
Member of Corporate Advisory Board
AGE
72
TENURE
4.1 yrs

Aditya Bardia

TITLE
Member of Scientific Advisory Board
TENURE
0.9 yrs

Greg Thurber

TITLE
Member of Scientific Advisory Board
TENURE
0.9 yrs

Bill Dickie

TITLE
Director
COMPENSATION
$45K
AGE
62
TENURE
0.8 yrs

Martin John Woodward

TITLE
Director
AGE
50
TENURE
0.3 yrs

Benjamin Krantz

TITLE
Director
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Aug 18 Buy Wjd Associates Inc. Company 22. Aug 18 22. Aug 18 400,000 €0.03 €13,246
23. Aug 18 Buy Paul Woodward Individual 22. Aug 18 22. Aug 18 350,000 €0.03 €11,590
23. Aug 18 Buy Alexander Krantz Individual 22. Aug 18 22. Aug 18 400,000 €0.03 €13,246
X
Management checks
We assess Advanced Proteome Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Advanced Proteome Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. The company develops and commercializes a platform that is intended for the chemical modification of protein therapeutics, primarily antibody-drug conjugates. Its proprietary technology targets delivery of anti-cancer drugs to cancerous tumors. The company has collaboration agreements with Heidelberg Pharma AG and Noria Pharmaceuticals Inc.; and collaboration and option agreement with ImmunoBiochem Corporation. Advanced Proteome Therapeutics Corporation is headquartered in Boston, Massachusetts.

Details
Name: Advanced Proteome Therapeutics Corporation
0E8
Exchange: DB
Founded:
CA$2,763,960
166,980,939
Website: http://www.advancedproteome.com
Address: Advanced Proteome Therapeutics Corporation
BioSquare,
650 Albany Street,
Boston,
Massachusetts, 02118,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV APC Common Shares TSX Venture Exchange CA CAD 14. Sep 1989
OTCPK APTC.F Common Shares Pink Sheets LLC US USD 14. Sep 1989
DB 0E8 Common Shares Deutsche Boerse AG DE EUR 14. Sep 1989
Number of employees
Current staff
Staff numbers
0
Advanced Proteome Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:37
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/04/01
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.